Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 28-31, 2024 in Miami, FL.
“The presentation of additional data from the EMERGENT program continues to illustrate the potential of KarXT as a novel treatment for schizophrenia, with its differentiated mechanism of action and safety and efficacy profile,” said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. “The impact of KarXT for patients and their care partners is promising, and we look forward to continuing our conversations with the U.S. Food & Drug Administration this year.”
Research to be presented at the meeting continues to demonstrate the potential of KarXT as a differentiated treatment option for adults living with schizophrenia. Notable data poster presentations include:
Low Long-Term Risk of Extrapyramidal Symptoms (EPS) with Muscarinic Agonist KarXT (Xanomeline and Trospium) (W86)
- Among pooled interim data from the Phase 3 outpatient, 52-week, open-label EMERGENT-4 and EMERGENT-5 studies, the incidence of extrapyramidal symptoms (EPS) adverse events (AEs) deemed to be treatment-related was 1% and the most commonly reported treatment-related EPS AE was akathisia (0.6%). KarXT was not associated with clinically meaningful changes from baseline in movement disorder scale scores on the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) over short or long-term studies.
Assessing Participant Experience with KarXT Treatment Using In-Trial Qualitative Interviews: Initial Findings from a Long-Term Phase 3 Trial in Schizophrenia (W24)
- In the Phase 3 outpatient, 52-week, open-label EMERGENT-5 trial evaluating the safety, tolerability and efficacy of KarXT in adults with schizophrenia, in-trial interviews were conducted with participants to provide qualitative insights to characterize their experience during the trial to better understand changes in symptoms and define meaningful treatment. Initial findings showed participants perceived an improvement in positive, negative, and cognitive symptoms of schizophrenia since initiating KarXT.
Lesen Sie auch
Complete abstracts may be accessed online here, and a full overview of abstracts to be presented at ASCP by BMS can be found below.